Rohit Sud, MD

Medical Oncologist

Gastrointestinal Malignancies

"Dr Sud is the best. I couldn’t ask for a better doctor. He takes time with you, he explains so that you understand what he’s talking to you about, he answers questions so that you understand. He’s very friendly he’s been my doctor for nine years and I wouldn’t trade him for anything."

Dr. Sud joined Ironwood Cancer & Research Centers in January 2012. After finishing his medical school in India, Dr. Sud completed his residency training at the Lincoln Medical Center, an affiliate of the Cornell University in New York, NY. He then served as Assistant Professor at the University of Arizona, where he served as the Chief of Inpatient Medicine. He completed his fellowship training at the Strong Memorial Hospital, University of Rochester, Rochester, NY. Dr. Sud has participated in several clinical research trials and has been published in peer-reviewed journals. His areas of clinical and research interests include several solid tumors, gastrointestinal, and hematological disorders. He is board certified in Internal Medicine, Hematology and Medical Oncology. He is at present an investigator in research trials.

Salvage therapy for relapsed and refractory Diffuse Large B-cell lymphoma – Impact of Prior Rituximab. Sud R, Friedberg JW. Hematologica Dec 2008.
American Society of Haematology abstract, Transcriptosome Profiling of B-CLL Identifies WNT-3A and ROR-1 as an Autocrine Mechanism in Cell Survival, J. Choi , R. Sud, H. Garewal, and D. Mahadevan.
Defining transformation of follicular lymphoma to diffuse large B cell lymphoma. R. Sud, D. Mahadevan., C. Spier. University of Arizona Cancer Center. Tucson AZ.
Recurrent Hypercalcemic crisis in non-secretory Multiple Myeloma. (New York Chapter, ACP-ASIM, Associate Abstract Competition Date: 11 / 1999)
Identification of factors contributing for the high 7-day revisit rate to the adult asthma Emergency Department. A performance improvement report. (Accepted for poster presentation at the American Lung Association/ American Thoracic Society International Conference, Toronto, May 2000)
The role of cognitive behavior therapy and pharmacotherapy for depression in diabetics towards glycemic control in an ambulatory care setting. A study assessing the influence of depression treatment on diabetic control. (Accepted for poster presentation at the New York Chapter of ACP-ASIM, New York, 2000)
Spontaneous Splenic rupture as the initial manifestation of idiopathic myelofibrosis. (New York Chapter ACP-ASIM Associates Abstact Competition, Date: 11 / 1999)
Utility of head CT scan in evaluation of patients presenting to the Emergency Department with altered mental status. (Accepted for poster presentation to American Critical Care Conference, San Francisco, 1998)

Oral Presentations

Acute Myeloid leukemia – novel prognostic factors in normal cytogenetics AML. Oral presentation at James P. Wilmot Cancer Center. August 2007.
Multiple Myeloma – role of thalidomide in maintenance therapy after autologous transplant. Oral presentation at James P. Wilmot Cancer Center symposium. October 2007.
Myelodysplastic syndrome – identification of new protein in 5q deletion MDS – an update from ASH 2007. Oral presentation at James P. Wilmot Cancer Center. December 2007.
Breast Cancer Genetics – role of BRCA mutations in treatment and prevention. Oral presentation at James P. Wilmot Cancer Center. February 2008.
Controversies in adjuvant hormonal treatment for early breast cancer. Oral presentation at James P. Wilmot Cancer Center. April 2008.
Adjuvant interferon in management of melanoma. Oral presentation at James P. Wilmot Cancer Center symposium. October 2008
Interim PET CT and risk-adapted therapy in lymphoma – current status and controversies. Oral presentation at James P. Wilmot Cancer Center symposium. March 2009.
Improvements in adjuvant therapy in early breast cancer – role of zolendronic acid. Oral presentation at James P. Wilmot Cancer Center. April 2009.